公司资料
Adagene 股价、新闻与催化剂
- 股票代码:
- ADAG
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- China and listed in the U
股票表现
3.83 USD (+3.51%)
收盘价
最后更新: 2026年8月17日
224M USD
市值
股价为何变动
As of Aug 17, 2026, ADAG closed up 3.51% at $3.83. No new same-company headline was identified in the current news window.
公司概览
业务概览
Adagene is a biotechnology company focused on next-generation antibody engineering and cancer immunotherapy. Its story is built around precision antibody design and the effort to create differentiated oncology medicines.
所在地与行业分类
Adagene is headquartered in China and listed in the U.S. market. It sits in oncology biotechnology with a platform-engineering identity.
商业模式特征
The company depends on translational validation, clinical data, and the ability to turn antibody engineering into clinical value. Investors watch proof-of-concept, partnerships, and capital runway.
生物医药行业定位
Adagene occupies a specialized antibody-engineering niche within biotech. It is catalyst-sensitive because the platform still needs to prove broad therapeutic differentiation.
未来催化剂
- Adagene’s catalysts are its immune-modulating antibody platform and any clinical or partnership update that shows the technology can still differentiate. The company still needs stronger human proof.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。